These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 25848468)

  • 1. Gut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemia.
    Fukui H
    World J Hepatol; 2015 Mar; 7(3):425-42. PubMed ID: 25848468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leaky Gut and Gut-Liver Axis in Liver Cirrhosis: Clinical Studies Update.
    Fukui H
    Gut Liver; 2021 Sep; 15(5):666-676. PubMed ID: 33071239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gut Microbiome-based Therapeutics in Liver Cirrhosis: Basic Consideration for the Next Step.
    Fukui H
    J Clin Transl Hepatol; 2017 Sep; 5(3):249-260. PubMed ID: 28936406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg.
    Arab JP; Martin-Mateos RM; Shah VH
    Hepatol Int; 2018 Feb; 12(Suppl 1):24-33. PubMed ID: 28550391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gut microbiota in alcoholic liver disease: pathogenetic role and therapeutic perspectives.
    Malaguarnera G; Giordano M; Nunnari G; Bertino G; Malaguarnera M
    World J Gastroenterol; 2014 Nov; 20(44):16639-48. PubMed ID: 25469033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intestinal Permeability Is a Mechanical Rheostat in the Pathogenesis of Liver Cirrhosis.
    Nishimura N; Kaji K; Kitagawa K; Sawada Y; Furukawa M; Ozutsumi T; Fujinaga Y; Tsuji Y; Takaya H; Kawaratani H; Moriya K; Namisaki T; Akahane T; Fukui H; Yoshiji H
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34203178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leaky gut and the liver: a role for bacterial translocation in nonalcoholic steatohepatitis.
    Ilan Y
    World J Gastroenterol; 2012 Jun; 18(21):2609-18. PubMed ID: 22690069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gut Microbiota and Hepatocellular Carcinoma.
    Tao X; Wang N; Qin W
    Gastrointest Tumors; 2015 May; 2(1):33-40. PubMed ID: 26673641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endotoxaemia in the pathogenesis of cytopenias in liver cirrhosis. Could oral antibiotics raise blood counts?
    Kalambokis G; Tsianos EV
    Med Hypotheses; 2011 Jan; 76(1):105-9. PubMed ID: 20832949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gut microbiota and host metabolism in liver cirrhosis.
    Usami M; Miyoshi M; Yamashita H
    World J Gastroenterol; 2015 Nov; 21(41):11597-608. PubMed ID: 26556989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gut-liver axis in cirrhosis: Are hemodynamic changes a missing link?
    Maslennikov R; Ivashkin V; Efremova I; Poluektova E; Shirokova E
    World J Clin Cases; 2021 Nov; 9(31):9320-9332. PubMed ID: 34877269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nitric oxide and the hyperdynamic circulation in cirrhosis: is there a role for selective intestinal decontamination?
    Rasaratnam B; Connelly N; Chin-Dusting J
    Clin Sci (Lond); 2004 Nov; 107(5):425-34. PubMed ID: 15270715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gut microbiota-related complications in cirrhosis.
    Gómez-Hurtado I; Such J; Sanz Y; Francés R
    World J Gastroenterol; 2014 Nov; 20(42):15624-31. PubMed ID: 25400446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Gut Dysbiosis in Liver Diseases: What Have We Learned So Far?
    Fukui H
    Diseases; 2019 Nov; 7(4):. PubMed ID: 31726747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies.
    Meroni M; Longo M; Dongiovanni P
    Nutrients; 2019 Nov; 11(11):. PubMed ID: 31689910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of gut-liver axis in the pathogenesis of liver cirrhosis and portal hypertension.
    Seo YS; Shah VH
    Clin Mol Hepatol; 2012 Dec; 18(4):337-46. PubMed ID: 23323248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.
    Suk KT; Kim DJ
    Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):193-204. PubMed ID: 30791767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mosapride Stabilizes Intestinal Microbiota to Reduce Bacterial Translocation and Endotoxemia in CCl
    Xu H; Xiong J; Xu J; Li S; Zhou Y; Chen D; Cai X; Ping J; Deng M; Chen J
    Dig Dis Sci; 2017 Oct; 62(10):2801-2811. PubMed ID: 28815345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes of Intestinal Functions in Liver Cirrhosis.
    Fukui H; Wiest R
    Inflamm Intest Dis; 2016 Apr; 1(1):24-40. PubMed ID: 29922655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonalcoholic fatty liver disease: for better or worse, blame the gut microbiota?
    Li DY; Yang M; Edwards S; Ye SQ
    JPEN J Parenter Enteral Nutr; 2013 Nov; 37(6):787-93. PubMed ID: 23538296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.